• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

    2/1/24 12:15:08 AM ET
    $NAVB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NAVB alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: January 31, 2024
    Accession Number: 0001437749-24-002312
    Submission Type: POS AM
    CIK: 0000810509
    Company Name: NAVIDEA BIOPHARMACEUTICALS, INC.
    File Number: 333-252847
    Get the next $NAVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAVB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Scott John K Jr. disposed of 2,270 units of Series G Redeemable Preferred Stock, closing all direct ownership in the company (SEC Form 4)

      4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)

      12/5/23 6:26:20 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Moss Dana J was granted 616,667 shares, increasing direct ownership by 247% to 866,667 units (SEC Form 4)

      4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)

      11/20/23 6:43:46 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stefanelli Jill was granted 691,667 shares, increasing direct ownership by 277% to 941,667 units (SEC Form 4)

      4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)

      11/20/23 6:10:13 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NAVB
    SEC Filings

    See more
    • SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

      EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

      2/1/24 12:15:04 AM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

      EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

      2/1/24 12:15:06 AM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

      EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

      2/1/24 12:15:11 AM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NAVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split

      Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was initially set to expire on July 8, 2025, ha

      5/21/25 2:52:00 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

      Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company") today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the "Section 382 Rights Plan"). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards ("NOLs") and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes

      3/31/25 6:08:00 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

      Navidea Biopharmaceuticals, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)" (ClinicalTrials.gov Identifier: NCT05246280) the "RA Trial." The purpose of the exploratory analysis was to optimize th

      7/3/24 4:30:00 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care